Business Context and Reporting Period
This Form 8-K Current Report from Alnylam Pharmaceuticals, Inc. (ALNY) covers events occurring on May 8, 2025, specifically the Company's 2025 Annual Meeting of Stockholders. The report details corporate governance actions, including the re-election of directors, approval of charter amendments, and ratification of auditors.
Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on corporate governance and stockholder voting results.
Material Changes
The primary material change reported is the amendment to the Company's Restated Certificate of Incorporation, filed with the Delaware Secretary of State on May 8, 2025. This amendment allows for officer exculpation. Additionally, the Company's stockholders approved the Second Amended and Restated 2018 Stock Incentive Plan.
Outlook, Risks, and Management Commentary
The filing contains no forward-looking guidance, management commentary on business outlook, or discussion of specific risks or contingencies. The document serves as a record of stockholder approvals. Key voting outcomes included:
- Director Elections: Stockholders re-elected four Class III directors (Carolyn R. Bertozzi, Margaret A. Hamburg, Colleen F. Reitan, and Amy W. Schulman) to serve until the 2028 annual meeting.
- Charter Amendment: Approved with 111,515,553 votes for and 7,120,857 votes against.
- Stock Incentive Plan: Approved with 114,044,496 votes for and 4,590,661 votes against.
- Executive Compensation: Approved in a non-binding advisory vote with 111,725,907 votes for and 6,909,706 votes against.
- Auditor Ratification: PricewaterhouseCoopers LLP was ratified as the independent auditor for the fiscal year ending December 31, 2025.
Key Facts for Investor Verification
- Verify the effective date of the Certificate of Amendment to the Restated Certificate of Incorporation (May 8, 2025).
- Confirm the terms of office for the newly elected Class III directors (until the 2028 annual meeting).
- Note the significant number of "Votes Against" for director Amy W. Schulman (14,370,696) compared to other nominees.
- Review the full text of the Second Amended and Restated 2018 Stock Incentive Plan referenced in the filing.
- Confirm the record date for the Annual Meeting was March 10, 2025, with 130,084,858 shares outstanding.